HOMOLOGY MEDICINES INC (FIXX) Stock Fundamental Analysis

NASDAQ:FIXX • US4380831077

0.9347 USD
+0.01 (+0.77%)
At close: Mar 25, 2024
0.892 USD
-0.04 (-4.57%)
After Hours: 3/25/2024, 8:23:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall FIXX gets a fundamental rating of 2 out of 10. We evaluated FIXX against 521 industry peers in the Biotechnology industry. The financial health of FIXX is average, but there are quite some concerns on its profitability. FIXX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • FIXX had negative earnings in the past year.
  • FIXX had a negative operating cash flow in the past year.
  • FIXX had negative earnings in each of the past 5 years.
  • FIXX had a negative operating cash flow in each of the past 5 years.
FIXX Yearly Net Income VS EBIT VS OCF VS FCFFIXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of FIXX (-133.57%) is worse than 85.71% of its industry peers.
  • FIXX's Return On Equity of -154.74% is on the low side compared to the rest of the industry. FIXX is outperformed by 67.69% of its industry peers.
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROIC N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
FIXX Yearly ROA, ROE, ROICFIXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • FIXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FIXX Yearly Profit, Operating, Gross MarginsFIXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • FIXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FIXX has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FIXX Yearly Shares OutstandingFIXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
FIXX Yearly Total Debt VS Total AssetsFIXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -8.72, we must say that FIXX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of FIXX (-8.72) is worse than 75.00% of its industry peers.
  • There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACC9.71%
FIXX Yearly LT Debt VS Equity VS FCFFIXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

  • FIXX has a Current Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of FIXX (7.25) is better than 69.56% of its industry peers.
  • A Quick Ratio of 7.25 indicates that FIXX has no problem at all paying its short term obligations.
  • The Quick ratio of FIXX (7.25) is better than 69.56% of its industry peers.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
FIXX Yearly Current Assets VS Current LiabilitesFIXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • FIXX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.16%.
  • FIXX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -64.06%.
  • Measured over the past years, FIXX shows a very negative growth in Revenue. The Revenue has been decreasing by -26.31% on average per year.
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%

3.2 Future

  • FIXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
  • The Revenue is expected to grow by 10.76% on average over the next years. This is quite good.
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FIXX Yearly Revenue VS EstimatesFIXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
FIXX Yearly EPS VS EstimatesFIXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FIXX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FIXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FIXX Price Earnings VS Forward Price EarningsFIXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FIXX Per share dataFIXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y9.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for FIXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

HOMOLOGY MEDICINES INC

NASDAQ:FIXX (3/25/2024, 8:23:28 PM)

After market: 0.892 -0.04 (-4.57%)

0.9347

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-09
Inst Owners0.11%
Inst Owner Change0%
Ins Owners15.02%
Ins Owner Change0%
Market Cap54.23M
Revenue(TTM)1.15M
Net Income(TTM)-112.95M
Analysts43.33
Price Target1.53 (63.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.28%
Min EPS beat(2)-33.05%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-10.74%
Min EPS beat(4)-33.05%
Max EPS beat(4)8.5%
EPS beat(8)4
Avg EPS beat(8)-3.52%
EPS beat(12)8
Avg EPS beat(12)7.79%
EPS beat(16)10
Avg EPS beat(16)7.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.16
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.02
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.45%
Cap/Sales 19.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -8.72
F-Score2
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)56.06%
Cap/Depr(5y)112.08%
Cap/Sales(3y)22.33%
Cap/Sales(5y)302.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%
EBIT growth 1Y30.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.61%
EBIT Next 3Y32.15%
EBIT Next 5Y37.25%
FCF growth 1Y16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.34%
OCF growth 3YN/A
OCF growth 5YN/A

HOMOLOGY MEDICINES INC / FIXX FAQ

What is the fundamental rating for FIXX stock?

ChartMill assigns a fundamental rating of 2 / 10 to FIXX.


What is the valuation status of HOMOLOGY MEDICINES INC (FIXX) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOMOLOGY MEDICINES INC (FIXX). This can be considered as Overvalued.


Can you provide the profitability details for HOMOLOGY MEDICINES INC?

HOMOLOGY MEDICINES INC (FIXX) has a profitability rating of 0 / 10.


How financially healthy is HOMOLOGY MEDICINES INC?

The financial health rating of HOMOLOGY MEDICINES INC (FIXX) is 6 / 10.


What is the earnings growth outlook for HOMOLOGY MEDICINES INC?

The Earnings per Share (EPS) of HOMOLOGY MEDICINES INC (FIXX) is expected to grow by 64.09% in the next year.